Aza-Carmona Miriam, Barca-Tierno Veronica, Hisado-Oliva Alfonso, Belinchón Alberta, Gorbenko-del Blanco Darya, Rodriguez Jose Ignacio, Benito-Sanz Sara, Campos-Barros Angel, Heath Karen E
Institute of Medical and Molecular Genetics (INGEMM), Hospital Universitario La Paz, Universidad Autónoma de Madrid, IdiPAZ, Madrid, Spain ; Centro de Investigación Biomédica en Enfermedades Raras (CIBERER), Instituto Carlos III, Madrid, Spain.
Dept. Celular Biology, Immunology & Neurosciences, Facultad de Medicina, Universidad de Barcelona, Barcelona, Spain.
PLoS One. 2014 Jan 8;9(1):e83104. doi: 10.1371/journal.pone.0083104. eCollection 2014.
SHOX and SHOX2 transcription factors are highly homologous, with even identical homeodomains. Genetic alterations in SHOX result in two skeletal dysplasias; Léri-Weill dyschondrosteosis (LWD) and Langer mesomelic dysplasia (LMD), while no human genetic disease has been linked to date with SHOX2. SHOX2 is, though, involved in skeletal development, as shown by different knockout mice models. Due to the high homology between SHOX and SHOX2, and their functional redundancy during heart development, we postulated that SHOX2 might have the same transcriptional targets and cofactors as SHOX in limb development. We selected two SHOX transcription targets regulated by different mechanisms: 1) the natriuretic peptide precursor B gene (NPPB) involved in the endochondral ossification signalling and directly activated by SHOX; and 2) Aggrecan (ACAN), a major component of cartilage extracellular matrix, regulated by the cooperation of SHOX with the SOX trio (SOX5, SOX6 and SOX9) via the protein interaction between SOX5/SOX6 and SHOX. Using the luciferase assay we have demonstrated that SHOX2, like SHOX, regulates NPPB directly whilst activates ACAN via its cooperation with the SOX trio. Subsequently, we have identified and characterized the protein domains implicated in the SHOX2 dimerization and also its protein interaction with SOX5/SOX6 and SHOX using the yeast-two hybrid and co-immunoprecipitation assays. Immunohistochemistry of human fetal growth plates from different time points demonstrated that SHOX2 is coexpressed with SHOX and the members of the SOX trio. Despite these findings, no mutation was identified in SHOX2 in a cohort of 83 LWD patients with no known molecular defect, suggesting that SHOX2 alterations do not cause LWD. In conclusion, our work has identified the first cofactors and two new transcription targets of SHOX2 in limb development, and we hypothesize a time- and tissue-specific functional redundancy between SHOX and SHOX2.
SHOX和SHOX2转录因子高度同源,甚至同源结构域完全相同。SHOX的基因改变会导致两种骨骼发育不良疾病,即勒里-韦伊软骨发育不全(LWD)和朗格肢中发育不良(LMD),而迄今为止尚未发现与SHOX2相关的人类遗传疾病。不过,不同的基因敲除小鼠模型显示,SHOX2参与骨骼发育。由于SHOX和SHOX2之间高度同源,且它们在心脏发育过程中具有功能冗余性,我们推测SHOX2在肢体发育中可能具有与SHOX相同的转录靶点和辅助因子。我们选择了两个受不同机制调控的SHOX转录靶点:1)参与软骨内骨化信号传导且直接由SHOX激活的利钠肽前体B基因(NPPB);2)聚集蛋白聚糖(ACAN),它是软骨细胞外基质的主要成分,通过SOX5/SOX6与SHOX之间的蛋白质相互作用,由SHOX与SOX三联体(SOX5、SOX6和SOX9)协同调控。通过荧光素酶检测,我们证明SHOX2与SHOX一样,直接调控NPPB,同时通过与SOX三联体协同作用激活ACAN。随后,我们利用酵母双杂交和免疫共沉淀检测,鉴定并表征了与SHOX2二聚化以及它与SOX5/SOX6和SHOX蛋白质相互作用相关的蛋白结构域。对不同时间点的人类胎儿生长板进行免疫组织化学分析表明,SHOX2与SHOX以及SOX三联体成员共同表达。尽管有这些发现,但在一组83例无已知分子缺陷的LWD患者中,未在SHOX2中发现突变,这表明SHOX2改变不会导致LWD。总之,我们的研究确定了SHOX2在肢体发育中的首个辅助因子和两个新的转录靶点,并且我们推测SHOX和SHOX2之间存在时间和组织特异性的功能冗余。